A Phase 1 interventional study of Trihexyphenidyl in Pediatric Disorder, Genetic Predisposition and Dystonia, Secondary, sponsored by Children's Mercy Hospital Kansas City. Recruiting at 1 site in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Children's Mercy Hospital Kansas City · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.
Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 32nd largest by planned enrollment of the 37 interventional ones that give a count, is one of 7 that started in 2024, is one of 4 in phase 1, reaches primary completion later than 31 of the 45 other live ones, and was the 73rd registered.
242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.
Browse Genetic Predisposition to Disease studies →37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:
University of Missouri-Columbia · Sites in United States
Ages 45–65 · Women only · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
Georgetown University · Sites in United States
Ages 45–74 · Women only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Women only
Christopher Reilly · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.
This study: 5 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 238 across 86 interventional studies indexed under Genetic Predisposition to Disease.
Median enrollment 225 across the 37 interventional studies, 560 across the 50 observational. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 87 have an industry lead sponsor. The 10 most frequent:
Children's Mercy Hospital Kansas City is the lead sponsor of 210 studies on the registry; 20 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.
Children's Mercy Hospital Kansas City has 1 study filed under Genetic Predisposition to Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Genetic Predisposition to Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05205356Boston Children's HospitalVIGOR: Virtual Genome Center for Infant Health | 2026-12-31 |
| NCT05020574University of California, San FranciscoMicrobiome and Association With Implant Infections | 2026-12-31 |
| NCT06962059Abramson Cancer Center at Penn MedicineHealthy Volunteers Study | 2027-01-15 |
| NCT06450171Dana-Farber Cancer InstituteEvaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study | 2027-01-31 |
| NCT05161169Brigham and Women's HospitalImplementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants | 2027-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 87 studies in Genetic Predisposition to Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.
This is a 16-week single-arm nonrandomized pilot study of trihexyphenidyl in children with dystonic cerebral palsy (DCP) to 1) evaluate the pharmacokinetics (PK) of trihexyphenidyl (THP) and variation in PK parameters between CYP2D6 and CYP2C19 genotypes and 2) evaluate the feasibility of a future exposure-controlled clinical trial of THP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receive trihexyphenidyl following the dose escalation schedule below: Week 1: 0.05 mg/kg BID Week 2: 0.05 mg/kg TID Week 3: 0.1 mg/kg TID Week 4: 0.15 mg/kg TID Week 5: 0.20 mg/kg TID Week 6-15: 0.25 mg/kg TID
Drug: Trihexyphenidyl
6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose
Difference in Cmax between CYP2D6 and CYP2C19 phenotype groups
Cmax will be measured in first-dose pharmacokinetic study on study day 1
Time frame: Baseline
Difference in AUC0-n between CYP2D6 and CYP2C19 phenotype groups
AUC0-n will be measured in first-dose pharmacokinetic study on study day 1
Time frame: Baseline
Difference in AUC0-∞ between CYP2D6 and CYP2C19 phenotype groups
AUC0-∞ will be measured in first-dose pharmacokinetic study on study day 1
Time frame: Baseline
Recruitment percentage
Measure percent of participants who were approached for the study that enrolled in the study
Time frame: Through study completion, an average of 2 years
Retention percentage
Measure percent of participants enrolled who completed the study
Time frame: Through study completion, an average of 2 years
Dystonia Efficacy Measures Outcome Completion
Measure percent of participants enrolled who were able to complete each dystonia efficacy measure (see secondary outcome measures)
Time frame: Through study completion, an average of 2 years
Number of participants with at least one adverse event as measured by the Safety Monitoring Uniform Report Form (SMURF)
Adverse events will only include those that are determined to be related to the study drug.
Time frame: Through study completion, an average of 2 years
Change from baseline in dystonia duration as measured by the Dyskinesia Impairment Scale, Version 2 (DIS-2) (exploratory)
The Dyskinesia Impairment Scale, Version 2 (DIS-2) is an updated version of the Dyskinesia Impairment Scale used to assess dystonia across multiple body regions. Duration of dystonia using subscale DIS-D are measured in 12 body regions during activity and rest. Dystonia duration scores are measured on a 4-point scale from 0 to 4 with 0 being dystonia is absent and 4 being dystonia is always present (≥90%).
Time frame: Baseline, 16 weeks
Change from baseline in dystonia amplitude as measured by the Dyskinesia Impairment Scale (exploratory)
Amplitude of dystonia using subscale DIS-D are measured in 12 body regions during activity and rest. Dystonia amplitude scores are measured on a 4-point scale from 0 to 4 with 0 being dystonia is absent and 4 being dystonia in maximal range of motion (≥90%).
Time frame: Baseline, 16 weeks
Change from baseline in dystonia as measured by the Quality of Upper Extremity Skills Test (QUEST) (exploratory)
Upper extremity function in 1 domain; grasp. 13 activities with item-level scores and three items for the tester to rate: hand function, spasticity, and cooperativeness. All scores are summed, and formulas are used to calculate percentages for this domain. Domain percentage is summed with a minimum score less than 0, and the maximum score is 100.
Time frame: Baseline, 16 weeks
Change in functional impact from baseline as measured by the Dyskinetic Cerebral Palsy Functional Impact Scale (D-FIS) (exploratory)
Functional impact scores are measured on a 5-point scale from 0 to 4 with 0 being dyskinesia may be present but has no impact on the named activity, and 4 being dyskinesia is present and prevents child from doing a named activity, even with help. An "NA" option indicates the activity is difficult but NOT due to dyskinesia.
Time frame: Baseline, 16 weeks
Change in priority scores in functional impact from baseline as measured by the Dyskinetic Cerebral Palsy Functional Impact Scale (D-FIS) (exploratory)
Priority scores are measured on a 4-point scale from 1 to 4 with 1 being an activity is not a priority and 4 being an activity is highest priority.
Time frame: Baseline, 16 weeks
Change in patient-driven performance from baseline as measured by the Canadian Occupational Performance Measure (exploratory)
Performance scores are measured on a 10-point scale with 1 being not able to do an activity at all and 10 being able to do an activity extremely well.
Time frame: Baseline, 16 weeks
Change in patient-driven goal satisfaction from baseline as measured by the Canadian Occupational Performance Measure (exploratory)
Satisfaction scores are measured on a 10-point scale with 1 being not satisfied at all with the way they do an activity to 10 being extremely satisfied with the way they do an activity.
Time frame: Baseline, 16 weeks
Change in caregiver's perspective about their child in 4 domains: health status, comfort, wellbeing, functional abilities, and ease of caregiving from baseline as measured by Caregiver Priorities and Child Health Index of Life with Disabilities
Scores for each domain and for the total survey are standardized and range from 0 to 100 with 0 being the worst and 100 being the best.
Time frame: Baseline, 16 weeks
Measure the acceptability of outcome measures at 16 weeks as measured by the Acceptability of Intervention Measure
Scores are measured on a 5-point scale from Completely Disagree to Completely Agree for items 1) The outcome measure meets my approval. 2) The outcome measure is appealing to me. 3) I like the outcome measure. 4) I welcome the outcome measure
Time frame: 16 weeks
Change in disease severity from baseline as measured by the Patient Global Impression of Severity (PGI-S) (exploratory)
The Patient Global Impression of Severity (PGI-S) is a single-item outcome measure assessing overall disease severity over the past week. Clinicians rate the participant's condition on a 5-point scale: none, mild, moderate, severe, or very severe. Higher scores indicate greater perceived severity.
Time frame: Baseline and 16 weeks
Change in overall status as measured by the Patient Global Impression of Change (PGI-C)
The Patient Global Impression of Change (PGI-C) is a single-item outcome assessing overall change since the start of the study. Participants and the clinician rate the participant's condition on a 7-point Likert scale ranging from very much improved to very much worse.
Time frame: Week 16
Plan to share: Yes — Pharmacokinetic data, including genotypes and THP levels, will be in publications for analysis replication. This will include participant genotypes and corresponding levels of THP, R-THP, and S-THP. Raw data and technical duplicates are available on request for result transparency and clinical trial design. CYP2D6 and CYP2C19 data will also be published; raw sequences go to NICHD's Data Hub (https://dash.nichd.nih.gov/), new haplotypes to PharmVar (https://www.pharmvar.org/). Recruitment, retention, and scientific methods outcomes will be published to guide future THP trials, though the study isn't powered for efficacy endpoints.
Supporting information: Study protocol, Statistical analysis plan
Time frame: The data will be made available at the time of the associated publication or at the end of the study period, whichever comes first. The datasets made available through publications in PubMed will be made available indefinitely. Sharing of raw data upon request will be accommodated for at least 10 years. Once genetic data are published or uploaded to DASH or PharmVar, they will be available indefinitely.
Access criteria: Access to raw pharmacokinetic data/samples and genetic samples will be controlled because it will only be available upon request. For DASH, a request for study data can be submitted and managed within their system.
Data sharing details ↗ · dash.nichd.nih.gov
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Nov 2029, 61 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trihexyphenidyl
Genetic Predisposition to Disease →
Children's Mercy Hospital Kansas City →